Adamantane
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Adamantane | |
|---|---|
| |
| |
| |
| IUPAC name | Tricyclo[3.3.1.13,7]decane |
| Identifiers | |
| CAS number | |
| SMILES | C1C2CC3CC1CC(C2)C3 |
| Properties | |
| Molecular formula | C10H16 |
| Molar mass | 136.23 g/mol |
| Appearance | White to off-white powder |
| Density | 1.07 g/cm³ (20 °C), solid |
| Melting point |
270 °C (543 K) |
| Solubility in water | Poorly soluble |
| Solubility in other solvents | Soluble in hydrocarbons |
| Structure | |
| Crystal structure | face-centred cubic |
| Dipole moment | 0 D |
| Hazards | |
| Main hazards | Flammable |
| S-phrases | 24/25/28/37/45 |
| Related Compounds | |
| Related compounds: | Memantine Rimantadine Amantadine |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references | |
|
WikiDoc Resources for Adamantane | |
|
Articles | |
|---|---|
|
Most recent articles on Adamantane | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Adamantane at Clinical Trials.gov Clinical Trials on Adamantane at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Adamantane
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Adamantane Discussion groups on Adamantane Patient Handouts on Adamantane Directions to Hospitals Treating Adamantane Risk calculators and risk factors for Adamantane
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Adamantane | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Adamantane (tricyclo[3.3.1.13,7]decane) is a colourless, crystalline compound with a camphor-like odour.[1][2] With a formula C10H16, it is a cycloalkane and also the simplest diamondoid. Adamantane was discovered in petroleum in 1933.[3] Its name derived from the Greek adamantinos (relating to steel or diamond), due to its diamond-like structure.[4] Adamantane is the most stable isomer of C10H16.
Synthesis
Adamantane was first synthesised by Prelog in 1941.[5] A more convenient method was found by Schleyer in 1957, from dicyclopentadiene by hydrogenation followed by acid-catalysed skeletal rearrangement.[6][7]
Uses
Adamantane itself enjoys few applications since it is merely an unfunctionalised hydrocarbon. It is used in some dry etching masks.[8] It is also used in some polymer formulations.
In solid-state NMR spectroscopy, adamantane is a common standard for chemical shift referencing.[9]
In dye lasers, adamantane may be used to extend the life of the gain medium; it cannot be photoionised under atmosphere because its absorption bands lie in the vacuum-ultraviolet region of the spectrum. Photoionization energies have been determined recently for adamantane as well as for several bigger diamondoids.[10]
Adamantane derivatives
Adamantane derivatives are useful in medicine, e.g. amantadine, memantine and rimantadine. Condensed adamantanes or diamondoids have been isolated from petroleum fractions, where they occur in small amounts. These species are of interest as molecular approximations of the cubic diamond framework, terminated with C-H bonds. 1,3-Dehydroadamantane is a member of the propellane family.
Due to its stability, specific steric properties and conformational rigidity, the 1-adamantyl group is a (bulky) substituent in organic and organometallic chemistry. Some of the first persistent carbenes featured adamantyl substituents.
Adamantane analogues
Many molecules adopt cage structures with adamantanoid structures. Particularly useful compounds with this motif include P4O6, As4O6, P4O10 (= (PO)4O6), P4S10 (= (PS)4S6), and N4(CH2)6.[11]
References
- ↑ SID 152429 -- PubChem Substance Summary. Retrieved on 14 October, 2005.
- ↑ ADAMANTANE(TRICYCLO(3.3.1.1)DECANE). Retrieved on 14 October, 2005.
- ↑ Landa, S.; Machácek, V. (1933). "". Collection Czech. Chem. Commun. 5: 1.
- ↑ Alexander Senning. Elsevier's Dictionary of Chemoetymology. Elsevier, 2006. ISBN 0444522395.
- ↑ Prelog, V., Seiwerth,R. (1941). "". Berichte 74: 1644 and 1769.
- ↑ Schleyer, P. von R. (1957). "A Simple Preparation of Adamantane". J. Am. Chem. Soc. 79: 3292-3292. doi:10.1021/ja01569a086.
- ↑ Schleyer, P. von R.; Donaldson, M. M.; Nicholas, R. D.; Cupas, C. "Adamantane", Organic Syntheses, Coll. Vol. 5, p.16 (1973); Vol. 42, p.8 (1962).
- ↑ ^ WATANABE, KEIJI; et al. (2001). RESIST COMPOSITION AND PATTERN FORMING PROCESS. United States Patent Application 20010006752. Bandwidth Market, Ltd. Retrieved on 14 October, 2005.
- ↑ Corey R. Morcombe and Kurt W. Zilm (2003). "Chemical Shift referencing in MAS solid state NMR". J. Magn. Reson. 162: 479-486. doi:10.1016/S1090-7807(03)00082-X.
- ↑ K. Lenzke, L. Landt, M. Hoener et al. (2007). "Experimental determination of the ionization potentials of the first five members of the nanodiamond series". J. Chem. Phys. 127: 084320.
- ↑ Vitall, J. J., "The Chemistry of Inorganic and Organometallic Compounds with Adamantane-Like Structures", Polyhedron, 1996, 15, 1585-1642
Influenza | |
|---|---|
| Influenza | Research - Vaccine - Avian influenza - Treatment - Genome sequencing - Season |
| Influenza viruses | Orthomyxoviridae - Influenza A - Influenza B - Influenza C |
| Subtypes of Influenza A virus | H1N1 - H1N2 - H2N2 - H3N1 - H3N2 - H3N8 - H5N1 - H5N2 - H5N3 - H5N8 - H5N9 - H7N1 - H7N2 - H7N3 - H7N4 - H7N7 - H9N2 - H10N7 |
| H5N1 | Genetic structure - Transmission and infection - Global spread - Clinical Trials - Human mortality |
| Antiviral drugs | Arbidol - adamantane derivatives (Amantadine, Rimantadine) - neuraminidase inhibitors (Oseltamivir, Peramivir, Zanamivir) Experimental (Peramivir) |
| Influenza vaccines | FluMist - Fluzone |
| Influenza pandemics | Asian Flu - Hong Kong Flu - Spanish flu - Fujian flu - Pandemic Severity Index |
| Outbreaks of Avian influenza | Croatia (2005) - India (2006) - UK (2007) - West Bengal (2008) |
| Influenza in non-human mammals | Canine influenza - Equine influenza (2007 Australian outbreak) - Swine flu |
de:Adamantan nl:Adamantaansk:Adamantán
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
